Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2011 (2011), Article ID 675858, 10 pages
http://dx.doi.org/10.1155/2011/675858
Review Article

Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries

1School of Health Sciences, University of Tampere, 33014 Tampere, Finland
2Faculty of Social Sciences, McMaster University, Hamilton, ON, Canada L85 4L8

Received 2 February 2011; Accepted 12 May 2011

Academic Editor: Marc Arbyn

Copyright © 2011 Kari Natunen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. X. Bosch, A. Lorincz, N. Muñoz, C. J. L. M. Meijer, and K. V. Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. View at Google Scholar · View at Scopus
  2. M. Arbyn, X. Castellsagué, S. de Sanjosé, L. Bruni, M. Saraiya, F. Bray et al., “Worldwide burden of cervical cancer in 2008,” Annals of Oncology. In press.
  3. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide, IARC Cancer Base No. 10, International Agency for Research on Cancer, Lyon, France, 2010.
  4. L. Hammarstedt, D. Lindquist, H. Dahlstrand et al., “Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer,” International Journal of Cancer, vol. 119, no. 11, pp. 2620–2623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. I. Conway, D. L. Stockton, K. A. A. S. Warnakulasuriya, G. Ogden, and L. M. D. Macpherson, “Incidence of oral and oropharyngeal cancer in United Kingdom (1990–1999)—recent trends and regional variation,” Oral Oncology, vol. 42, no. 6, pp. 586–592, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. K. Chaturvedi, E. A. Engels, W. F. Anderson, and M. L. Gillison, “Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 612–619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. M. Braakhuis, O. Visser, and C. René Leemans, “Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults,” Oral Oncology, vol. 45, no. 9, pp. E85–E89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. De Vuyst, G. M. Clifford, M. C. Nascimento, M. M. Madeleine, and S. Franceschi, “Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis,” International Journal of Cancer, vol. 124, no. 7, pp. 1626–1636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Auluck, G. Hislop, C. Bajdik, C. Poh, L. Zhang, and M. Rosin, “Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience,” Cancer, vol. 116, no. 11, pp. 2635–2644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Blomberg, A. Nielsen, C. Munk, and S. K. Kjaer, “Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites,” International Journal of Cancer, vol. 129, no. 3, pp. 733–741, 2010. View at Google Scholar
  11. S. Marur, G. D'Souza, W. H. Westra, and A. A. Forastiere, “HPV-associated head and neck cancer: a virus-related cancer epidemic,” The Lancet Oncology, vol. 11, no. 8, pp. 781–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. V. Barnabas, P. Laukkanen, P. Koskela, O. Kontula, M. Lehtinen, and G. P. Garnett, “Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses,” PLoS Medicine, vol. 3, no. 5, Article ID e138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Trottier and A. N. Burchell, “Epidemiology of mucosal human papillomavirus infection and associated diseases,” Public Health Genomics, vol. 12, no. 5-6, pp. 291–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. B. H. Yang, F. I. Bray, D. M. Parkin, J. W. Sellors, and Z. F. Zhang, “Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost,” International Journal of Cancer, vol. 109, no. 3, pp. 418–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Laukkanen, P. Koskela, E. Pukkala et al., “Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland,” Journal of General Virology, vol. 84, no. 8, pp. 2105–2109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. H. W. Chesson and P. J. White, “Influence of epidemic phase on the cost-effectiveness of a prevention intervention for sexually transmitted infection: an exploratory analysis,” Sexually Transmitted Infections, vol. 83, no. 1, pp. I25–I29, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Ferlay, F. Bray, P. Pisani, and D. M. Parkin, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base, No. 5, Version 2.0, IARC Press, Lyon, France, 2004.
  18. D. M. Parkin and F. Bray, “Chapter 2: the burden of HPV-related cancers,” Vaccine, vol. 24, supplement 3, pp. S11–S25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. F. X. Bosch, A. Lorincz, N. Muñoz, C. J. L. M. Meijer, and K. V. Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. View at Google Scholar · View at Scopus
  20. A. R. Kreimer, G. M. Clifford, P. Boyle, and S. Franceschi, “Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review,” Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 2, pp. 467–475, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Miralles-Guri, L. Bruni, A. L. Cubilla, X. Castellsagué, F. X. Bosch, and S. de Sanjosé, “Human papillomavirus prevalence and type distribution in penile carcinoma,” Journal of Clinical Pathology, vol. 62, no. 10, pp. 870–878, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. H. Brewster and L. A. Bhatti, “Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002,” British Journal of Cancer, vol. 95, no. 1, pp. 87–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. A. E. Grulich, F. Jin, E. L. Conway, A. N. Stein, and J. Hocking, “Cancers attributable to human papillomavirus infection,” Sexual Health, vol. 7, no. 3, pp. 244–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Hammarstedt, D. Lindquist, H. Dahlstrand et al., “Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer,” International Journal of Cancer, vol. 119, no. 11, pp. 2620–2623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Näsman, P. Attner, L. Hammarstedt et al., “Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?” International Journal of Cancer, vol. 125, no. 2, pp. 362–366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. H. Shiboski, B. L. Schmidt, and R. C. K. Jordan, “Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years,” Cancer, vol. 103, no. 9, pp. 1843–1849, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Clifford, S. Franceschi, M. Diaz, N. Muñoz, and L. L. Villa, “Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases,” Vaccine, vol. 24, supplement 3, pp. S26–S34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. R. Brown, S. K. Kjaer, K. Sigurdsson et al., “The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years,” Journal of Infectious Diseases, vol. 199, no. 7, pp. 926–935, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Paavonen, P. Naud, J. Salmerón et al., “Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women,” The Lancet, vol. 374, no. 9686, pp. 301–314, 2009. View at Publisher · View at Google Scholar
  30. C. M. Wheeler, S. K. Kjaer, K. Sigurdsson et al., “The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years,” Journal of infectious diseases, vol. 199, no. 7, pp. 936–944, 2009. View at Google Scholar
  31. B. J. Braakhuis, P. J. Snijders, and C. R. Leemans, “Human papillomavirus and oropharyngeal cancer,” New England Journal of Medicine, vol. 357, no. 11, p. 1157, 2007. View at Google Scholar · View at Scopus
  32. S. K. Kjaer, C. Munk, J. F. Winther, H. O. Jørgensen, C. J. L. M. Meijer, and A. J. C. van den Brule, “Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 6, pp. 1528–1533, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. J. Wawer, A. A. Tobian, G. Kigozi et al., “Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda,” The Lancet, vol. 377, no. 9761, pp. 209–218, 2011. View at Publisher · View at Google Scholar
  34. L. M. Chen, G. Li, L. R. Reitzel et al., “Matched-pair analysis of race or ethnicity in outcomes of head and neck cancer patients receiving similar multidisciplinary care,” Cancer Prevention Research, vol. 2, no. 9, pp. 782–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Settle, M. R. Posner, L. M. Schumaker et al., “Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients,” Cancer Prevention Research, vol. 2, no. 9, pp. 776–781, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. K. Chaturvedi, “Beyond cervical cancer: burden of other HPV-related cancers among men and women,” Journal of Adolescent Health, vol. 46, no. 4, pp. S20–S26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. K. Kjær, A. J.C. van den Brule, J. E. Bock et al., “Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?” Cancer Epidemiology Biomarkers and Prevention, vol. 6, no. 10, pp. 799–805, 1997. View at Google Scholar
  38. N. Muñoz, I. Kato, F. X. Bosch et al., “Risk factors for HPV DNA detection in middle-aged women,” Sexually Transmitted Diseases, vol. 23, no. 6, pp. 504–510, 1996. View at Google Scholar
  39. I. Silins, I. Kallings, and J. Dillner, “Correlates of the spread of human papillomavirus infection,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 9, pp. 953–959, 2000. View at Google Scholar · View at Scopus
  40. M. C. Rousseau, E. L. Franco, L. L. Villa et al., “A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 5, pp. 469–476, 2000. View at Google Scholar · View at Scopus
  41. N. Muñoz, X. Castellsagué, A. B. de González, and L. Gissmann, “Chapter 1: HPV in the etiology of human cancer,” Vaccine, vol. 24, supplement 3, pp. S1–S10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. A. S. Kapeu, T. Luostarinen, E. Jellum et al., “Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within nordic biobanks,” American Journal of Epidemiology, vol. 169, no. 4, pp. 480–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Palmroth, P. Namujju, A. Simen-Kapeu et al., “Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes,” Scandinavian Journal of Infectious Diseases, vol. 42, no. 5, pp. 379–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. B. Namujju, H. M. Surcel, R. Kirnbauer et al., “Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women,” Scandinavian Journal of Infectious Diseases, vol. 42, no. 6-7, pp. 522–526, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Sangani, G. Rutherford, and D. Wilkinson, “Population-based interventions for reducing sexually transmitted infections, including HIV infection,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD001220, 2004. View at Google Scholar
  46. S. H. Averbach, P. E. Gravitt, R. G. Nowak et al., “The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe,” AIDS, vol. 24, no. 7, pp. 1035–1042, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. S. Smith, S. Moses, M. G. Hudgens et al., “Increased risk of HIV acquisition among kenyan men with human papillomavirus infection,” Journal of Infectious Diseases, vol. 201, no. 11, pp. 1677–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. K. K. Smith-McCune, S. Shiboski, M. Z. Chirenje et al., “Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections,” PLoS One, vol. 5, no. 4, article e10094, 2010. View at Publisher · View at Google Scholar
  49. M. Schiffman, P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder, “Human papillomavirus and cervical cancer,” Lancet, vol. 370, no. 9590, pp. 890–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Palefsky, “HPV infection in the HIV-positive host: molecular interactions and clinical implications,” in Proceedings of the Lancet Conference, HPV and Cancer, Amsterdam, The Netherlands, November 2010.
  51. E. Läärä, N. E. Day, and M. Hakama, “Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes,” Lancet, vol. 1, no. 8544, pp. 1247–1249, 1987. View at Google Scholar · View at Scopus
  52. J. Peto, C. Gilham, J. Deacon et al., “Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort,” British Journal of Cancer, vol. 91, no. 5, pp. 942–953, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Sankaranarayanan, L. Gaffikin, M. Jacob, J. Sellors, and S. Robles, “A critical assessment of screening methods for cervical neoplasia,” International Journal of Gynecology and Obstetrics, vol. 89, supplement 2, pp. S4–S12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Stanley and L. L. Villa, “Monitoring HPV vaccination,” Vaccine, vol. 26, no. 1, pp. A24–A27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Levi, F. Lucchini, E. Negri, S. Franceschi, and C. la Vecchia, “Cervical cancer mortality in young women in Europe: patterns and trends,” European Journal of Cancer, vol. 36, no. 17, pp. 2266–2271, 2000. View at Google Scholar
  56. M. Sant, T. Aareleid, F. Berrino et al., “EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary,” Annals of Oncology, vol. 14, no. 5, pp. V61–V118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Gondos, E. Chokunonga, H. Brenner et al., “Cancer survival in a southern african urban population,” International Journal of Cancer, vol. 112, no. 5, pp. 860–864, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. L. A. G. Ries, M. P. Eisner, and C. L. Kosary, SEER Cancer Statistics Review, 1975–2001, National Cancer Institute, Bethesda, Md, USA, 2004.
  59. J. Paavonen, P. Naud, J. Salmerón et al., “Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women,” The Lancet, vol. 374, no. 9686, pp. 301–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. L. L. Villa, “Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine,” International Journal of Infectious Diseases, vol. 11, supplement 2, pp. S17–S25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Lehtinen, A. Simen Kapeu, A. Toriola, and J. Dillner, “Tonsillar Cancers Caused by HPV types -16/-18 - a new indication for HPV 16-/-18 vaccination?” HPV Today. In press.
  62. L. L. Villa, K. A. Ault, A. R. Giuliano et al., “Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18,” Vaccine, vol. 24, no. 27-28, pp. 5571–5583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Petäjä, H. Keränen, T. Karppa et al., “Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years,” Journal of Adolescent Health, vol. 44, no. 1, pp. 33–40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. M. P. David, K. Hardt, F. Tibaldi et al., “Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by CervarixTM: modelling of sustained antibody responses,” in Proceedings of the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases, Graz, Austria, 2008.
  65. S. J. Goldie, M. O'Shea, M. Diaz, and S. Y. Kim, “Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications,” Reproductive Health Matters, vol. 16, no. 32, pp. 86–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. P. B. Namujju, T. Waterboer, C. Banura, R. Muwonge, E. K. Mbidde, R. Byaruhanga et al., “Risk of seropositivity to multiple oncogenic human papillomavirus (HPV) types among HIV positive and HIV negative Ugandan women,” submitted to Journal of General Virology.
  67. M. Merikukka, M. Kaasila, P. B. Namujju et al., “Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33,” International Journal of Cancer, vol. 128, no. 5, pp. 1114–1119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Lehtinen and J. Paavonen, “Vaccination against human papillomaviruses shows great promise,” Lancet, vol. 364, no. 9447, pp. 1731–1732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. S. S. Huang, V. L. Hinrichsen, A. E. Stevenson et al., “Continued impact of pneumococcal conjugate vaccine on carriage in young children,” Pediatrics, vol. 123, no. 1, pp. E1–E11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. WHO, “Global immunization data,” 2009, http://www.who.int/immunization_monitoring/en/.
  71. S. L. Kulasingam and E. R. Myers, “Potential health and economic impact of adding a human papillomavirus vaccine to screening programs,” Journal of the American Medical Association, vol. 290, no. 6, pp. 781–789, 2003. View at Publisher · View at Google Scholar
  72. G. D. Sanders and A. V. Taira, “Cost effectiveness of a potential vaccine for Human papillomavirus,” Emerging Infectious Diseases, vol. 9, no. 1, pp. 37–48, 2003. View at Google Scholar · View at Scopus
  73. S. J. Goldie, M. Kohli, D. Grima et al., “Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine,” Journal of the National Cancer Institute, vol. 96, no. 8, pp. 604–615, 2004. View at Google Scholar · View at Scopus
  74. A. V. Taira, C. P. Neukermans, and G. D. Sanders, “Evaluating human papillomavirus vaccination programs,” Emerging Infectious Diseases, vol. 10, no. 11, pp. 1915–1923, 2004. View at Google Scholar · View at Scopus
  75. S. J. Goldie, J. J. Kim, K. Kobus et al., “Cost-effectiveness of HPV 16, 18 vaccination in Brazil,” Vaccine, vol. 25, no. 33, pp. 6257–6270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Brisson, N. van de Velde, P. de Wals, and M. C. Boily, “The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada,” Vaccine, vol. 25, no. 29, pp. 5399–5408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. E. H. Elbasha, E. J. Dasbach, and R. P. Insinga, “Model for assessing human papillomavirus vaccination strategies,” Emerging Infectious Diseases, vol. 13, no. 1, pp. 28–41, 2007. View at Google Scholar · View at Scopus
  78. J. J. Kim, B. Andres-Beck, and S. J. Goldie, “The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting,” British Journal of Cancer, vol. 97, no. 9, pp. 1322–1328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. J. J. Kim, M. Brisson, W. J. Edmunds, and S. J. Goldie, “Modeling cervical cancer prevention in developed countries,” Vaccine, vol. 26, no. 10, pp. K76–K86, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. J. Kim, K. E. Kobus, M. Diaz, M. O'Shea, H. Van Minh, and S. J. Goldie, “Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy,” Vaccine, vol. 26, no. 32, pp. 4015–4024, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Kulasingam, L. Connelly, E. Conway et al., “A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program,” Sexual Health, vol. 4, no. 3, pp. 165–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Diaz, J. J. Kim, G. Albero et al., “Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India,” British Journal of Cancer, vol. 99, no. 2, pp. 230–238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. P. A. Tookey and C. S. Peckham, “Surveillance of congenital rubella in Great Britain, 1971–96,” British Medical Journal, vol. 318, no. 7186, pp. 769–770, 1999. View at Google Scholar · View at Scopus
  84. T. Kubba, “Human papillomavirus vaccination in the United Kingdom: what about boys?” Reproductive Health Matters, vol. 16, no. 32, pp. 97–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. V. Brown and K. A. J. White, “The HPV vaccination strategy: could male vaccination have a significant impact?” Computational and Mathematical Methods in Medicine, vol. 11, no. 3, pp. 223–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. L. R. Stanberry, “Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines,” Herpes, vol. 11, no. 3, pp. A161–A169, 2004. View at Google Scholar · View at Scopus
  87. G. P. Garnett, “Role of herd immunity in determining the effect of vaccines against sexually transmitted disease,” Journal of Infectious Diseases, vol. 191, supplement 1, pp. S97–S106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. K. S. Reisinger, S. L. Block, E. Lazcano-Ponce et al., “Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial,” Pediatric Infectious Disease Journal, vol. 26, no. 3, pp. 201–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. K. M. French, R. V. Barnabas, M. Lehtinen et al., “Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland,” British Journal of Cancer, vol. 96, no. 3, pp. 514–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Lehtinen, K. M. French, J. Dillner, J. Paavonen, and G. Garnett, “Sound implementation of HPV vaccination,” Future Medicine, vol. 5, no. 3, pp. 289–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. D. G. Regan, D. J. Philp, J. S. Hocking, and M. G. Law, “Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia,” Sexual Health, vol. 4, no. 3, pp. 147–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Shebaya, A. Sutherland, O. Levine, and R. Faden, “Alternatives to national average income data as eligibility criteria for international subsidies: a social justice perspective,” Developing World Bioethics, vol. 10, no. 3, pp. 141–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. V. D. Tsu and C. E. Levin, “Making the case for cervical cancer prevention: what about equity?” Reproductive Health Matters, vol. 16, no. 32, pp. 104–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Denny, M. Quinn, and R. Sankaranarayanan, “Chapter 8: screening for cervical cancer in developing countries,” Vaccine, vol. 24, supplement 3, pp. S71–S77, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. G. P. Garnett and H. C. Waddell, “Public health paradoxes and the epidemiological impact of an HPV vaccine,” Journal of Clinical Virology, vol. 19, no. 1-2, pp. 101–111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Bingham, J. Kidwell Drake, and D. S. LaMontagne, “Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings,” Archives of Pediatrics & Adolescent Medicine, vol. 163, no. 5, pp. 455–461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. G. D. Zimet, N. Liddon, S. L. Rosenthal, E. Lazcano-Ponce, and B. Allen, “Chapter 24: psychosocial aspects of vaccine acceptability,” Vaccine, vol. 24, supplement 3, pp. S201–S209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. B. F. Stanton, “Assessment of relevant cultural considerations is essential for the success of a vaccine,” Journal of Health, Population and Nutrition, vol. 22, no. 3, pp. 286–292, 2004. View at Google Scholar · View at Scopus
  99. I. Agurto, S. Arrossi, S. White et al., “Involving the community in cervical cancer prevention programs,” International Journal of Gynecology and Obstetrics, vol. 89, supplement 2, pp. S38–S45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. S. C. Woodhall, M. Lehtinen, T. Verho, H. Huhtala, M. Hokkanen, and E. Kosunen, “Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland,” Journal of Adolescent Health, vol. 40, no. 5, pp. 466–469, 2007. View at Publisher · View at Google Scholar
  101. J. L. Winkler, S. Wittet, R. M. Bartolini et al., “Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean,” Vaccine, vol. 26, no. 11, pp. L73–L79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Madhivanan, K. Krupp, M. N. Yashodha, L. Marlow, J. D. Klausner, and A. L. Reingold, “Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India,” Vaccine, vol. 27, no. 38, pp. 5203–5208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. L. P. Wong, “Physicians' experiences with HPV vaccine delivery: evidence from developing country with multiethnic populations,” Vaccine, vol. 27, no. 10, pp. 1622–1627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. J. D. Allen, G. D. Coronado, R. S. Williams et al., “A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability,” Vaccine, vol. 28, no. 24, pp. 4027–4037, 2010. View at Publisher · View at Google Scholar
  105. S. A. Francis, J. Nelson, J. Liverpool, S. Soogun, N. Mofammere, and R. J. Thorpe Jr., “Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa,” Vaccine, vol. 28, no. 50, pp. 8026–8032, 2010. View at Publisher · View at Google Scholar
  106. G. D. Zimet and S. L. Rosenthal, “HPV vaccine and males: issues and challenges,” Gynecologic Oncology, vol. 117, no. 2, supplement 1, pp. S26–S31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Becker-Dreps, W. A. Otieno, N. T. Brewer, K. Agot, and J. S. Smith, “HPV vaccine acceptability among Kenyan women,” Vaccine, vol. 28, no. 31, pp. 4864–4867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Kibur, P. Koskela, J. Dillner et al., “Seropositivity to multiple sexually transmitted infections is not common,” Sexually Transmitted Diseases, vol. 27, no. 8, pp. 425–430, 2000. View at Google Scholar · View at Scopus
  109. WHO, “Human papillomavirus vaccines: WHO position paper,” Weekly Epidemiological Record, vol. 15, no. 84, pp. 118–131, 2009. View at Google Scholar
  110. L. S. Palacio-Mejía, G. Rangel-Gómez, M. Hernández-Avila, and E. Lazcano-Ponce, “Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico,” Salud Publica de Mexico, vol. 45, supplement 3, pp. S315–S325, 2003. View at Google Scholar · View at Scopus
  111. S. Arrossi, S. Ramos, M. Paolino, and R. Sankaranarayanan, “Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina,” Reproductive Health Matters, vol. 16, no. 32, pp. 50–58, 2008. View at Publisher · View at Google Scholar
  112. R. Murillo, M. Almonte, A. Pereira et al., “Cervical cancer screening programs in Latin America and the Caribbean,” Vaccine, vol. 26, no. 11, pp. L37–L48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. E. Pukkala and E. Weiderpass, “Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971–1995),” International Journal of Cancer, vol. 81, no. 1, pp. 56–61, 1999. View at Publisher · View at Google Scholar
  114. World Health Organization, B. W. Stewart, and P. Kleihues, Eds., “World cancer report,” WHO and IARC Press, 2003. View at Google Scholar
  115. P. Braveman, “Health disparities and health equity: concepts and measurement,” Annual Review of Public Health, vol. 27, pp. 167–194, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. Principles of Equity and Health, “EUR/ICP/RPD 414,” World Health Organization Regional Office for Europe, Copenhagen, Denmark, 1990.
  117. P. Braveman and S. Gruskin, “Defining equity in health,” Journal of Epidemiology and Community Health, vol. 57, no. 4, pp. 254–258, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. D. R. Gwatkin, “10 best resources onhealth equity,” Health Policy and Planning, vol. 22, no. 5, pp. 348–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. E. L. Franco, “Commentary: health inequity could increase in poor countries if universal HPV vaccination is not adopted,” British Medical Journal, vol. 335, no. 7616, pp. 378–379, 2007. View at Google Scholar · View at Scopus
  120. E. D. O'Brien, R. S. Bailie, and P. L. Jelfs, “Cervical cancer mortality in Australia: contrasting risk by aboriginality, age and rurality,” International Journal of Epidemiology, vol. 29, no. 5, pp. 813–816, 2000. View at Google Scholar · View at Scopus
  121. E. Malmqvist, G. Helgesson, J. Lehtinen, K. Natunen, and M. Lehtinen, “The ethics of implementing human papillomavirus vaccination in developed countries,” Medicine, Healthcare and Philosophy, vol. 14, no. 1, pp. 19–27, 2011. View at Publisher · View at Google Scholar
  122. S. Wittet, “Hepatitis B. Vaccine Introduction: Lessons Learned In Advocacy, Communication, and Training,” PATH, Seattle, Wash, USA, 2001. View at Google Scholar
  123. L. Brabin, D. P. Greenberg, L. Hessel, R. Hyer, B. Ivanoff, and P. Van Damme, “Current issues in adolescent immunization,” Vaccine, vol. 26, no. 33, pp. 4120–4134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. W. Stevens and D. Walker, “Adolescent vaccination in the developing world: time for serious consideration?” Vaccine, vol. 22, no. 5-6, pp. 781–785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. UNICEF, Progress for Children: A World Fit for Children, Statistical Review, no.6, UNICEF, New York, NY, USA, 2007.
  126. U.N. Econ and Soc. Council [ECOSOC], “The millennium development goals report,” 2008, U.N. Doc. E.O8.I.18,12-19. View at Google Scholar
  127. UNICEF, State of the World’s Children, 2009.
  128. J. Harries, J. Moodley, M. A. Barone, S. Mall, and E. Sinanovic, “Preparing for HPV vaccination in South Africa: key challenges and opinions,” Vaccine, vol. 27, no. 1, pp. 38–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. M. A. Kane, J. Sherris, P. Coursaget, T. Aguado, and F. Cutts, “Chapter 15: HPV vaccine use in the developing world,” Vaccine, vol. 24, supplement 3, pp. S132–S139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Sellors, “HPV Vaccination in the Developing World,” in Proceedings of the Lancer Conference on HPV, November 2010.
  131. I. Agurto, A. Bishop, G. Sánchez, Z. Betancourt, and S. Robles, “Perceived barriers and benefits to cervical cancer screening in Latin America,” Preventive Medicine, vol. 39, no. 1, pp. 91–98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. N. J. Veldhuijzen, P. J. F. Snijders, P. Reiss, C. J. L. M. Meijer, and J. H. H. M. van de Wijgert, “Factors affecting transmission of mucosal human papillomavirus,” The Lancet Infectious Diseases, vol. 10, no. 12, pp. 862–874, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. R. L. Winer, J. P. Hughes, Q. Feng et al., “Condom use and the risk of genital human papillomavirus infection in young women,” New England Journal of Medicine, vol. 354, no. 25, pp. 2645–2654, 2006. View at Publisher · View at Google Scholar